Indication
Glycogen Storage Disease Type II (Infantile Onset)
1 clinical trial
2 products
Clinical trial
An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 YearsStatus: Recruiting, Estimated PCD: 2027-04-01
Product
Cipaglucosidase alfaProduct
Miglustat